The First Diagnostic Kit in Personal Cancer Treatment Developed in Teknopark Istanbul

The first diagnostic kit was developed in Technopark Istanbul
The first diagnostic kit was developed in Technopark Istanbul

Gene-IST, operating at Cube Incubation, Technopark Istanbul's Incubation Center, has produced a real-time 'diagnostic kit' that determines which possible treatments and at which drug doses cancer patients will respond. The Prognostic Cancer PD-L1 Real Time PCR kit, which has no global competitor, can be used in every PCR device around the world.

Thanks to the developed kit, possible mutations and treatment methods can be detected, so the course of the cancer can be predicted. The kit is also easily available for its low cost.

Teknopark Istanbul, where new and advanced technological studies are carried out without slowing down, was another first. Prognostic Cancer PD-L1 Real-Time PCR Kit, which is the first and only product produced by Gene-IST, which conducts its studies at the Incubation Center of Technopark Istanbul, as a result of the projects in the world, determines which possible treatments and at which drug doses cancer patients will respond. does.

Gene-IST, which was established in 2018 in Cube Incubation, Technopark Istanbul's Incubation Center, provides R&D, biotechnology, training and consultancy, kit production, import and export services in the fields of molecular genetics and pharmacology. Pharmacogenetic test kits, developed by the company, allow the application of individualized, rational drug therapies that change the drug response in cancerous tissues and determine genetic factors affecting survival. With diagnosis-treatment response kits, toxic effects that may occur due to personal genetic differences are determined. Thus, individualized more effective treatments can be applied. Costs due to unnecessary drug use and unwanted side effects can also be avoided to a large extent.

Cancer Progress Can Be Predictable

With the real-time PCR kit produced as part of the project 'Investigating the Molecular Causes of the Course of Cancer and Differences in Response to Treatment Between Patients and Developing a Diagnostic Kit for this' project, possible mutations and treatment methods can be detected thanks to the real-time PCR kit, so the course of the cancer can be predicted and personalized treatment methods are developed. The kit also provides reliable results in a very short time and is easily available with low cost. The kit, which can determine the possible treatment method for the patient, enables the drug doses to be adjusted individually to the patient and enables effective treatment of patients with targeted drugs. The kit can also detect drug resistance in tumor tissue DNA, detect gene differences that may cause drug toxicity, and can be used worldwide in any PCR device, regardless of brand.

Prof. Dr. Belgin Ornament: “The kit we produce is national and local. Since it is the first and only product to detect individual variations of the PD-L1 gene, one of the target molecules of immune checkpoint inhibitors in both national and international markets, we have no competitors in domestic and foreign markets. Numerous medical analysis laboratories, which currently provide services on cancer genetics, conduct tests by typing cancerous tissues and cells, and partly to determine individual susceptibility to cancer. But these studies do not provide information about the course of the cancer. Immune checkpoint inhibitors; "It has been developed in the last 10 years and is still under patent protection, so it is extremely expensive drugs that have no substitutes."

Ornamental also stated that some progress has been made with the new generation chemotherapy and immunotherapy drugs, but the responses to the treatment are still not sufficient, “The course of cancer is determined by the genetic characteristics of the tumor. Due to some mutations in the tumor tissue, the patient's response to cancer drugs may not be complete. These mutations cause the drug to be ineffective and waste unnecessary time and money. On the other hand, the toxic effects of the drugs and the inadequate treatment efficiency due to drug resistance are among the other problems encountered.

The company cooperates with France-Lorraine University Cancer Institute, Netherlands-Erasmus University Medical Center, Italy-Rome University 'La Sapienza' Clinical Biochemistry Unit, determination of new pharmacogenetic biomarkers belonging to different clinics, development and application of new technologies in the field of metabolomics, the person who can be used in cancer treatment It conducts projects within the scope of determining genes that play a role in special effective drug treatments.

Similar Ads

Be the first to comment